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ABSTRACT 
 Campylobacter is the leading cause of foodborne illness worldwide and is often 
associated with consumption and/or mishandling of contaminated poultry products. Probiotic use 
in poultry has been an effective strategy in reducing other enteric foodborne pathogens but has 
not proven consistent for Campylobacter. As Campylobacter resides and utilizes intestinal mucin 
for growth, isolates selected on the basis of mucin utilization might be a strategy to screen for 
efficacious probiotic bacterium. In this study, bacterial isolates demonstrating increased growth 
rates in mucin, in vitro (trials 1 or 2), or isolates demonstrating a reduction of Campylobacter 
counts when co-incubated with mucin, in vitro (trials 3 or 4) were selected for their ability to 
reduce Campylobacter colonization in four bird trials.  In trials 1 or 2, ninety day-of-hatch chicks 
were randomly divided into 9 treatment groups (n=10 chicks/treatment) and treated individually 
with one of four bacterial isolates demonstrating increased growth in media containing mucin.  
The treatments included a positive Campylobacter control (no isolate) or four isolates grown in 
media with or without mucin prior to inoculation. In trials 3 or 4, sixty day-of-hatch chicks were 
divided into six treatment groups (n=10 chicks/treatment) receiving either no isolate (positive 
Campylobacter control) or dosed with five individual isolates all demonstrating the ability to 
reduce Campylobacter counts when co-incubated with mucin, in vitro.  These isolates were 
grown in media containing mucin prior to inoculation.  In all four trials, birds were gavaged with 
individual isolates at day-of-hatch and orally challenged with a four strain mixture C. jejuni on 
day 7. Ceca were collected at day 14 for Campylobacter enumeration. Results from these first 
two trials demonstrated two individual isolates, one with increased growth rates when grown in 
mucin or one isolate incubated without mucin, consistently reduced cecal Campylobacter counts 
(1.5 to 4 log reduction) when compared with controls.  In follow-up trials with isolates selected 
  
 
for their ability to directly reduce Campylobacter counts when co-incubated with mucin, in vitro, 
one isolate consistently reduced cecal Campylobacter counts by approximately 1.5 logs. These 
results support the potential use of mucin to preselect isolates for their ability to reduce enteric 
Campylobacter colonization. 
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CHAPTER 1: LITERATURE REVIEW 
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INTRODUCTION 
Food-borne illness is one of the greatest problems in public health today, which is mostly 
due to consumption of food contaminated with bacteria, viruses, parasites and/or toxins (WHO, 
2011). It has been reported that food-borne illnesses are likely to occur in developing and 
underdeveloped countries due to poor sanitation and poor socioeconomic conditions prevailing 
in those countries (WHO, 2012a). However, recent studies have documented an increasing 
number of food-borne diseases in developed countries (Humphery et al., 1993; CDC, 2011). 
Even with one of the safest food supplies in the world, it has been reported that 1 in 6 Americans 
get sick due to food-borne illness, resulting in 128,000 hospitalizations and 3,000 deaths each 
year in the United States (CDC, 2011). It has been estimated that food-borne illnesses cause 
economic losses worth $77.7 billion per annum in the United States (Scharff, 2012). 
Campylobacter infection in humans is one of the leading causes of food-borne illness worldwide 
(WHO, 2012b). In the United States alone, approximately 13.85 cases were reported per every 
100,000 people in 2013 (CDC, 2014) and it is estimated to cause economic loss of $1.7 billion 
annually (Hoffmann et al., 2012). Similarly in the European Union, approximately nine million 
human campylobacteriosis cases have been estimated with a resulting economic loss of € 2.4 
billion annually (EFSA, 2011). 
CHARACTERISTICS OF CAMPYLOBACTER 
Historical overview 
 In 1886, Theodor Escherich first observed a unique spiral shaped bacteria in the stool 
samples from infants with diarrhea (Escherich, 1886), which was later identified as 
Campylobacter. During the early 1900s, McFadyean and Stockman first isolated Campylobacter 
spp. from the fetal tissues of aborted sheep (Butzler, 2004; Skirrow, 2006). Since then several 
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scientists isolated similar organisms from aborted bovine fetuses, dysentery in calves and sheep 
(Jones et al., 1931; Doyle, 1944). Initially the organisms were classified under the genus Vibrio, 
but in 1963 Sebald and Véron separated Campylobacter from the genus Vibrio and proposed a 
new genus, Campylobacter (Sebald and Véron, 1963). Campylobacter markedly differ from 
Vibrio due to their microaerophilic growth, non-fermentative metabolism and low DNA base 
composition (Sebald and Véron, 1963). In 1973, Véron and Chatelain further classified Vibrio-
like organisms into the type species; C. fetus along with C. coli, C. jejuni and C. sputorum 
because of their different characteristics from genus Vibrio (Véron and Chatelain, 1973). The 
Genus Campylobacter was later classified under a new family Campylobacteraceae which also 
included other genera; Helicobacter, Arcobacter, Sulfurospirillum and Wolinella (Vandamme 
and De Ley, 1991). There are at least 17 identified species of Campylobacter (Lastovica, 2006; 
Debruyne et al., 2008); however Campylobacter jejuni and Campylobacter coli are responsible 
for more than 95% of the human campylobacteriosis cases (Park, 2002; Snelling et al., 2005) 
Morphological characteristics 
The word Campylobacter originated from the Greek words, “kampulos” and “bacter” 
meaning “curved” and “rod” respectively (Sebald and Véron, 1963). All members of the genus 
Campylobacter are gram negative non-spore forming slender spirally-curved rods, measuring 
0.2-0.8 µm wide and 0.5-5 µm long (Smibert, 1978; Thomas et al., 1998; Debruyne et al., 2008). 
Campylobacter have a single polar flagellum that is approximately double the length of the cell 
which makes them highly motile with a characteristic cork-screw like motility (Smibert, 1978; 
Debruyne et al., 2008). As exceptions, some species, such as C. gracilis, are non-motile, and C. 
showae have multiple flagella (Debruyne et al., 2008).  
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In vitro growth requirements 
Campylobacter spp. are fastidious organisms, needing complex growth media and 
microaerophilic environmental conditions for their growth (Buck and Smith, 1987; Kelly, 2001; 
Park, 2002; Garénaux et al., 2008). Optimal growth is observed at 42°C under microaerophilic 
conditions (5% oxygen, 10% carbon dioxide and 85% nitrogen; Park, 2002). Despite the high 
temperature requirement for their growth, C. jejuni displays physiological activity even at 4°C 
(Hazeleger et al., 1998). It has been reported that C. jejuni can resist environmental stressors by 
changing its morphology from spiral-bacilla to coccoid forms, which is characterized by loss of 
culturability (Kelly, 2001), however they still remain viable (Rollins and Colwell, 1986). Also, 
unfavorable environmental growth conditions such as changes in temperature, pH, osmolarity 
and loss of nutrients in the medium are responsible for transition from spiral to coccoid viable 
but nonculturable (VBNC) state (Rollins and Colwell, 1986; Lázaro et al., 1999; Moore, 2001). 
It has been found that this VBNC state possesses the ability to infect hosts (Saha et al., 1991; 
Cappelier et al., 1999a; Baffone et al., 2006). However, contradictory opinions have been 
proposed about the ability of VBNC forms to become metabolically active and produce disease 
upon exposure to favorable conditions (Jones et al., 1991; Beumer et al., 1992; Korsak and 
Popowski, 1997; Cappelier et al., 1999a; Cappelier et al., 1999b). The molecular mechanism 
underlying the VBNC state development and resuscitation are still unknown (Pinto et al., 2013).  
Environmental reservoirs and sources of Campylobacter infection. 
 Campylobacter spp. are ubiquitous and normally found in a wide range of warm-blooded 
animals (Humphrey et al., 2007), including food-producing animals such as pigs (Nesbakken et 
al., 2003), sheep (Firehammer and Myers, 1981; Stanley and Jones, 2003), beef cattle, turkeys 
(Zhao et al., 2001) and chickens (King, 1962; Skirrow, 1977). Apart from food-producing 
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animals, contact with pets can also serve as a source of human Campylobacter infections 
(Deming et al., 1987; Kapperud et al., 1992). Consumption of untreated water may be another 
route of human Campylobacter infection ( Vogt et al., 1982; Palmer et al., 1983; Taylor et al., 
1983; Hopkins et al., 1984). Some research articles also suggested that raw or unpasteurized milk 
is a source of Campylobacter infection resulting in human gastroenteritis (Blaser et al., 1979; 
Porter and Reid, 1980; Robinson and Jones, 1981). Consumption of fruits and vegetables (Evans 
et al., 2003) and mushrooms (Doyle and Schoeni, 1986) have been reported as minor sources of 
Campylobacter transmission to humans (Rosef and Kapperud, 1983). Among the various causes 
of human infections, poultry is considered the primary source of infections (King, 1962; Skirrow, 
1977). Handling of Campylobacter contaminated chicken and consumption of undercooked 
chicken are the major sources for human campylobacteriosis (Hopkins and Scott, 1983; Ikram et 
al., 1994; Neimann et al., 2003; Friedman et al., 2004). It has also been found that cross 
contamination of raw chicken with other uncooked food items during food preparation in the 
kitchen is a major route for Campylobacter infections in humans (Boer and Hahne, 1990; Mylius 
et al., 2007; Luber, 2009) 
CAMPYLOBACTER IN HUMANS 
Human Incidence 
It was shown that Campylobacter spp. are able to cause infections in animals in the early 
1900s; however it wasn’t reported in humans until about 1980 (Skirrow, 1977; Silva et al., 
2011). With the development of filter techniques (Dekeyser et al., 1972) and selective medium 
(Skirrow, 1977). Campylobacter has been recognized as the most common cause of food-borne 
diarrheal illness in humans (Allos, 2001; EFSA/ECDC, 2013; CDC, 2014). Cases of human 
campylobacteriosis are seen in both developed and developing countries, and are likely to occur 
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often in children, immune-compromised and elderly persons (Tauxe et al., 1992; Corry and 
Atabay, 2001). The incidence in infants (24.08 per 100,000) is higher as opposed to adults (14.54 
per 100,000) in United States (CDC, 2014). Campylobacter infections in male to female ratio is 
approximately 1.2-1 (Louis et al., 2005; Olson et al., 2008). However, the reason behind such 
high incidence in males compared to females is not fully understood (Friedman, 2000). It has 
been reported that the incidence may vary with the season; peak incidences occurring from June-
August in North America, Europe, UK and Canada (Nylen et al., 2002; Nelson and Harris, 2011; 
Lal et al., 2012). 
In the United States, the CDC has reported 13.83 incidences per 100,000 people in 2013 
which is greater than previous reports (CDC, 2014). This reported incidence might be lower than 
the actual incidence due to many underdiagnosed and underreported cases (Mead et al., 1999; 
Samuel et al., 2004). The European Food Safety Authority and the European Center for Disease 
Control and Prevention jointly estimated 220,201 Campylobacter cases in 2011 which is 2.2% 
more than in 2010 (EFSA, 2013).  It is also reported as the most frequent zoonotic disease after 
salmonellosis in 2011 (EFSA/ECDC, 2013). In Australia, England and Wales, annual cases of 
225,000 and 500,000 were reported respectively (Hall et al., 2008; Nichols et al., 2012). Other 
countries such as Germany, Netherlands and Finland have also reported increasing cases of 
campylobacteriosis (Nakari et al., 2010). 
Pathogenesis of Campylobacter 
The molecular mechanisms involved in the pathogenesis of Campylobacter are not clear 
(Ketley, 1997; Svensson et al., 2014). However it is believed that adhesion, colonization and 
invasion of host intestinal epithelium play a pivotal role in producing symptoms associated with 
campylobacteriosis (Ketley, 1997). Campylobacter possesses the fibronectin binding proteins 
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cadF, FlpA and periplasmic or membrane associated protein (PEB 1) that is responsible for host 
cell binding and colonization (Konkel et al., 1997; van Vliet and Ketley, 2001; Young et al., 
2007; Konkel et al., 2010). Host cell invasion and gastroenteritis is mediated by protein secretion 
via the flagellar type III secretion system (Larson et al., 2008). The infection is further aided by 
flagellar-driven motility and Campylobacter invasion antigen (Dasti et al., 2010). It has been 
found that internalization of C. jejuni into host cells is triggered by the combined effects of the 
microfilaments and microtubules of host cells (Biswas et al., 2003). Johnson and Lior (1988) 
reported that C. jejuni produces a toxin called cytolethal distending toxin (Cdt). Cdt causes a host 
cell cycle arrest, preventing cells from entering the M phase, inducing host cell apoptosis 
(Whitehouse et al., 1998; Dasti et al., 2010). The genes encoding Cdt were sequenced for C. 
jejuni in late 1990s (Pickett et al., 1996; Bang et al., 2001) and for C. coli and C. fetus in late 
2007 (Asakura et al., 2007, 2008). 
Human Infections 
 Campylobacter infection is one of the leading causes of bacterial gastroenteritis in 
humans (Blaser et al., 1983; Allos, 2001; CDC, 2014). It has been suggested that children and 
immunocompromised people are more susceptible to Campylobacter infections (Allos, 2001). 
Thermotolerant Campylobacter spp. specifically C. jejuni and C. coli, together account for 
approximately 95% of human campylobacteriosis cases worldwide (Park, 2002; EFSA/ECDC, 
2013). An infective dose as low as 500-800 live cells may be sufficient to cause illness in 
humans (Robinson, 1981; Black et al., 1988). The incubation period ranges from 2-5 days, but 
has been reported up to 10 days (Butzler, 2004). In most patients symptoms may include 
diarrhea, abdominal cramps, malaise, myalgia and fever (Skirrow, 1977; Butzler, 2004). 
Diarrhea may be loose, watery or bloody, suggestive of ulcerative colitis due to the invasive 
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nature of C. jejuni (Blaser, 1997). Extra-intestinal manifestations including meningitis (Goossens 
et al., 1986), osteomyelitis (Vandenberg et al., 2003) and neonatal sepsis are less frequently seen 
(Butzler, 2004). Campylobacteriosis is generally a self-limiting disease and the affected patients 
may recover without any treatment (Allos and Blaser, 1995; Rosenquist et al., 2003).  Some 
cases of campylobacteriosis have been associated with serious post-infectious complications 
such as Guillain-Barré syndrome, reactive arthritis, irritable bowel syndrome and inflammatory 
bowel disease (Gumpel et al., 1981; Spiller and Garsed, 2009). 
 Guillian-Barré syndrome. Guillian-Barré syndrome (GBS) is one of the potential long-
term severe complications of Campylobacter infection. It is a neuromuscular disease 
characterized by ascending paralysis that causes weakness of limbs, respiratory muscles and loss 
of reflexes (Allos, 1997). It has been identified that 20-40% of the GBS cases were associated 
with a preceeding C. jejuni infection (Mishu and Blaser, 1993). Approximately 1 in 1000 cases 
of Campylobacter infections may develop GBS (Allos, 1997). Patients usually develop GBS 1-3 
weeks after the onset of Campylobacter enteritis (Butzler, 2004). Approximately 20% of GBS 
patients requires hospitalization in the intensive care unit for respiratory ventilation (WHO 
2012b).  
It has been postulated that molecular mimicry between lipooligosacccharides of C. jejuni 
and host GM1 gangliosides may cause the development of autoantibodies and play a role in the 
pathogenesis of GBS (Yuki et al., 1993, 2004). There are four subtypes of GBS: 1) acute motor 
axonal neuropathy (AMAN); 2) acute inflammatory demyelinating polyadiculoneuropathy 
(AIDP); 3) acute motor and sensory axonal neuropathy (AMSAN) and 4) Miller Fishers 
syndrome. Among these four subtypes of GBS, Campylobacter infections are most frequently 
associated with the AMSAN subtype (Kuwabara, 2004).  
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 Reactive arthritis. Reactive arthritis (ReA) is a spondyloarthropathy and occurs 
subsequent to microbial gastrointestinal infections, including Campylobacter (Carter and 
Hudson, 2009; Wu and Schwartz, 2008). Symptoms of ReA may include inflammation of joints, 
tissues, skin and tendons (Pope et al., 2007; Townes, 2010). It has been estimated that 1-5% of 
Campylobacter cases may result in reactive arthritis (Pope et al., 2007), however estimates of up 
to 16% have been reported (Ajene et al., 2013). Though children are more likely to get 
Campylobacter infections, ReA is more common in adults (Carter, 2006; Pope et al., 2007). 
Pathophysiology of this disease is still not clear. However one hypothesis involves antibody 
production against pathogens having affinity to HLA-B27 and another hypothesis is impaired 
cellular immunity (decreased interleukin-2 production) against the inciting microorganism 
correlating with disease development (Wu and Schwartz, 2008).  
 Irritable Bowel Syndrome. Irritable bowel syndrome (IBS) is a recurring functional 
gastrointestinal disorder characterized by frequent abdominal pain (three or more per month) or 
discomfort linked with defecation or change in bowel habit and abdominal bloating (Quigley et 
al., 2009). Prevalence of IBS in North America and Europe ranges from 10-16% (Quigley et al., 
2009). It is believed that Campylobacter infections as an antecedent infection account for about 
10% of IBS cases (Spiller and Garsed, 2009). The exact mechanism by which Campylobacter 
causes symptoms of IBS is not completely understood, however Campylobacter spp. is known to 
produce cytotoxins and some of them are believed to be associated with development of IBS 
(Thornley et al., 2001). 
 Inflammatory Bowel Disease. Inflammatory bowel disease (IBD) is a collective term for 
ulcerative colitits and Crohn’s disease (Papadakis and Targan, 1999). It is a chronic relapsing 
disease characterized by diarrhea, constipation, tenesmus, abdominal cramps, fever, pain and/or 
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rectal bleeding with bowel movement, (Bernstein et al., 2009). Campylobacter jejuni has been 
isolated from 10% of IBD cases (Gradel et al., 2009). Campylobacter promotes translocation of 
non-invasive bacteria by disrupting transcellular transport across the intestinal epithelium 
playing a role in the pathogenesis of IBD (Kalischuk et al., 2009).  
Treatment 
 Campylobacter infections are generally self-limiting and do not require antibiotic 
therapy, if antimicrobial therapy is needed fluoroquinolones are the drug of choice (Allos, 2001). 
However, in the past few years, fluoroquinolone resistant Campylobacter strains are emerging 
(Allos, 2001). Campylobacter spp. may also be resistant to other antibiotics including 
ciprofloxacin, bacitracin, novobiocin, rifampin, trimethoprim, vancomycin and tetracycline 
(Taylor and Courvalin, 1988; Kuschner et al., 1995; Engberg et al., 2001). Currently, 
erythromycin is used most frequently to treat Campylobacter infection due to its low toxicity, 
narrow spectrum and low cost (Allos and Blaser, 1995; Allos, 2001).   
CAMPYLOBACTER IN POULTRY 
Epidemiology of Campylobacter in poultry 
Campylobacter is ubiquitous in poultry flocks and it has been found that the percentage 
of broiler flocks colonized with Campylobacter varies from country to country (Newell and 
Fearnley, 2003). In the United States and Great Britain nearly 90% of flocks are colonized with 
Campylobacter (Evans and Sayers, 2000; Stern et al., 2001b), 41.1% in Germany (Atanassova 
and Ring, 1999) and 47.5% in Japan (Haruna et al., 2012). However, in Europe prevalence rates 
vary from 18 to 90%, with the northernmost countries having remarkably lower percentages than 
southernmost countries (Newell and Fearnley, 2003).  
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 Many research findings have shown variability in Campylobacter contamination with 
retail poultry products. Factors such as sample collection, detection methodology, season, 
geographical location and production practices may contribute to variability in Campylobacter 
contamination in poultry and poultry products (Lee and Newell, 2006). An epidemiological study 
in Greater Washington D.C. suggested that approximately 70.7% of raw chicken meat was 
contaminated with Campylobacter (Zhao et al., 2001). Other studies have revealed as high as 90-
100% of the raw chicken meat is contaminated with Campylobacter (Suzuki and Yamamoto, 
2009). 
Campylobacter colonization in birds 
 Campylobacter is generally nonpathogenic in poultry (Beery et al., 1988; Stern et al., 
1988). Environmental contamination is the primary source of infection in newly placed chicks 
(Shane, 1992). Chicks around the age of 2-3 weeks get colonized with Campylobacter in their 
intestinal tract as a commensal organism (Beery et al., 1988). The infectious dose for chicken has 
been reported to be as low as 50 organisms (Achen et al., 1998; Knudsen et al., 2006). 
Campylobacter predominantly resides in the lower part of the intestine, notably in the ceca, and 
concentrations may reach up to 108 CFU per gram of cecal contents (Beery et al., 1988; Stern et 
al., 1988; Achen et al., 1998). A study conducted in UK reported that there is no seasonal 
variation regarding the prevalence of Campylobacter in broiler flocks (Humphery et al., 1993). 
Nevertheless, some studies found a summer peak in the prevalence of positive flocks (Wallace et 
al., 1997; Nylen et al., 2002). The mechanism of colonization in the bird’s intestine is not fully 
elucidated. However, it is hypothesized that chemoattraction of C. jejuni to mucin plays a 
significant role in colonization; C. jejuni uses mucin as a substrate and colonizes in high numbers 
in the cecal crypts (Beery et al., 1988). Similarly, an immunological investigation on host 
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immune response to Campylobacter in chickens suggested that down regulation of certain genes 
in the host by Campylobacter plays a vital role in the persistent high level of colonization 
(Meade et al., 2009). In most cases, Campylobacter localizes in the intestines. However, 
systemic invasion to organs such as liver, spleen, heart and lungs has also been reported (Young 
et al., 1999; Meade et al., 2009). 
Transmission 
 Horizontal transmission. Several studies have shown a wide range of hosts for 
Campylobacter, wild birds, domestic birds (Luechtefeld et al., 1980; Glünder et al., 1992), 
rodents (Cabrita et al., 1992) and insects (Jacobs-Reitsma et al., 1995). Horizontal transmission 
is the predominant mode of transmission of Campylobacter in poultry (Loc Carrillo et al., 2005; 
Silva et al., 2011). Poultry flocks naturally become colonized from the above mentioned sources 
and Campylobacter positive birds rapidly shed the organisms in the feces which act as a source 
for other birds (Jacobs-Reitsma et al., 1995; Achen et al., 1998; Mead, 2002), which then spreads 
rapidly from bird to bird making the entire flock contaminated (Loc Carrillo et al., 2005; 
Horrocks et al., 2009). The rapidity of the shift from un-colonized to almost 100% colonization 
of Campylobacter in a flock is aided by coprophagic behavior of chicks and via contamination of 
food and water sources (Montrose et al., 1985; Keener et al., 2004). 
Vertical transmission. Transmission of C. jejuni from parent hen to chicks is controversial. 
Vertical transmission of any bacteria can take place by either primary (contamination of egg 
content in the hen’s reproductive tract) or secondary (contamination of the eggshell with fecal 
material after lay) infection of the egg (Sahin et al., 2003a). Many researchers have found the 
presence of Campylobacter in various parts of the male and female reproductive tracts of poultry 
(Cox et al., 2002; Cole et al., 2004) indicating a possibility of vertical transmission of 
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Campylobacter to chicks. Several investigations have been conducted to verify the possibility of 
vertical transmission of Campylobacter in poultry (Doyle, 1984; Clark and Bueschkens, 1985; 
Shanker et al., 1986). In their earlier studies, Clark and Bueschkens (1985) inoculated fertile 
eggs with C. jejuni, and demonstrated that 11% of the resulting chicks had Campylobacter in 
their intestinal tract. However, naturally it is not easy for Campylobacter to get into the egg 
content via egg shell penetration and even if it does contaminate the egg contents, it is not likely 
to survive for more than 48 h stored at room temperature (Doyle, 1984; Shanker et al., 1986). In 
contrast to these findings, some researchers demonstrated that Campylobacter can remain viable 
inside egg yolk for up to 14 days, but <8 days inside the air sac and albumen (Clark and 
Bueschkens, 1986).  
PREHARVEST CONTROL STRATEGIES OF CAMPYLOBACTER IN POULTRY 
 With increasing cases of human campylobacteriosis, development of intervention 
strategies are necessary to control and reduce Campylobacter in poultry and poultry products to 
minimize human infections. Reducing the bacterial concentration in poultry prior to processing 
would be beneficial, as cross contamination between fecal contaminated carcasses and meat may 
occur during processing. Risk assessment studies conducted by Rosenquist and his colleagues 
(2003) predicted that a 2 log reduction of the Campylobacter on chicken carcasses can reduce the 
human incidence by 30 fold. Many pre-harvest intervention strategies have been evaluated with 
varying results. Some of them are briefly described below which may be used as potential 
control measures to reduce the Campylobacter counts in poultry and poultry products. 
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Biosecurity 
 Biosecurity is the protection of farm animals from various types of infectious agents by 
using different types of measures such as use of protective clothing, cleaning and disinfecting of 
farm house, provision of clean water, restricting the movement of people or animals between 
farms, etc. (Silva et al., 2001; Vandeplas et al., 2008). Studies have demonstrated that adopting 
standard biosecurity methods led to an approximate 50% reduction of Campylobacter prevalence 
in broiler flocks (Gibbens et al., 2001). Similarly, a report from two Dutch broiler farms 
suggested that introduction of hygiene measures significantly reduced the Campylobacter 
prevalence in broiler flocks (van de Giessen et al., 1998). A review on biosecurity-based 
interventions by Newell and colleagues (2011) suggested that diligent application of biosecurity 
measures is required to reduce flock prevalence. However, complete elimination of 
Campylobacter from flocks is unlikely (Wagenaar et al., 2006; Vandeplas et al., 2008). 
Moreover, the costs involved with the adoption of such strict on farm biosecurity measures limits 
the practicality of biosecurity (Fraser et al., 2010). 
Bacteriocins 
 Bacteriocins are small biologically active protein compounds of approximately 5- 6 
kilodalton, produced by some strains of bacteria that can inhibit the growth of other closely 
related bacteria (Klaenhammer, 1993; Cleveland et al., 2001). Both Gram positive and Gram 
negative bacteria such as,  Lactobacillus, Lactococcus, Pediococcus, Carnobacterium, 
Enterococcus, Escherichia, Bacillus, Paenibacillus, Staphylococcus, Pseudomonas and 
Clostridium have been reported to produce bacteriocins (Svetoch and Stern, 2010). Bacteriocins 
application in poultry processing was initiated in 1994 with the test against Listeria 
monocytogenes using nisin (Mahadeo and Tatini, 1994). Similarly, a literature review on 
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bacteriocins suggest the potential use of bacteriocins for the reduction or elimination of many 
food-borne pathogens (Joerger, 2003). Bacteriocins produced by certain strains of Bacillus 
circulans and Paenibacillus polymyxa were found to be inhibitory to Campylobacter growth in 
vitro (Svetoch et al., 2005). Stern and colleagues (2005) reported that bacteriocins (B602) 
produced by P. polymyxa reduced cecal C. jejuni to undetectable levels in chickens. 
Subsequently, in a second study, inclusion of a microencapsulated bacteriocin (OR 7) in chicken 
feed for 3 days (day 7 to day 10) reduced cecal Campylobacter counts from 1.3 log CFU/g to 
undetectable levels, whereas control groups were colonized at 7-8 log CFU/g in 10-day-old 
broiler chickens (Stern et al., 2006). An additional study utilizing bacteriocins produced by P. 
polymyxa and Lactobacillus salivarius have shown cecal Campylobacter coli reductions to 
undetectable levels in turkey poults (Cole et al., 2006). Although research has shown promising 
results on bacteriocins against Campylobacter in poultry, bacteriocins can be degraded easily 
inside the host gut due to its proteinaceous nature (Joerger, 2003). It is expensive to adapt 
techniques such as microencapsulation, to prevent the enzymatic digestion of bacteriocins in the 
gastrointestinal tract (Joerger, 2003; Svetoch et al., 2005). In addition, implementation requires 
approval from the U.S. Food and Drug Administraion (FDA) which would require extensive and 
expensive safety and efficacy studies. So far only one bacteriocin (Nisin) has GRAS (generally 
recognized as safe) status (Joerger, 2003). Moreover, it has been found that Campylobacter 
develops resistance against bacteriocins which further limits their use in poultry (Hoang et al., 
2011a, b). 
Bacteriophage 
 Bacteriophages are viruses capable of infecting and killing specific bacteria (Huff et al., 
2005; Hagens and Loessner, 2007). Bacteriophages that infect and replicate in bacteria 
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subsequently killing the host cells are virulent bacteriophages, which are particularly important 
for reducing pathogenic bacteria (Huff et al., 2005). Campylobacter specific phages have been 
isolated from chicken excreta, retail poultry, abattoir effluent, sewage and other animal as well as 
human sources (Atterbury et al., 2003b; Connerton et al., 2004). Several studies were conducted 
to evaluate the potential application of bacteriophage to reduce cecal colonization of 
Campylobacter in broiler chickens (Loc Carrillo et al., 2005; Wagenaar et al., 2005; El-Shibiny, 
et al., 2009; Carvalho et al., 2010). Loc Carrillo and co-workers (2005) demonstrated phage 
treatment of C. jejuni colonized broiler chickens resulted in Campylobacter counts decreasing in 
range from 0.5 and 5 log CFU/g of cecal contents compared to the Campylobacter positive 
group. Additionally, they reported that variations in Campylobacter reductions were related to 
the administration dose of phage, type of phage used and time elapsed after administration. 
Although a sharp decrease in cecal C. jejuni is noted immediately after phage administration, C. 
jejuni re-establishes itself over time (Loc Carrillo et al., 2005; Wagennar et al., 2005). This 
phenomenon supports the application of bacteriophage a few days before slaughter could be 
more effective for reducing Campylobacter counts in market age birds (Wagenaar et al., 2005). 
In addition, it has also been observed that bacteriophage administration in the feed is more 
effective than oral gavage (Carvalho et al., 2010). Introduction of Campylobacter specific 
bacteriophage on artificially Campylobacter contaminated chicken skin showed a promising 
result in reduction of recoverable Campylobacter cells from treated chicken skin samples 
(Atterbury et al., 2003a). In contrast, another study on bacteriophage application on chicken meat 
samples stored at 4oC did not reduce Campylobacter counts (Orquera et al., 2012). 
Bacteriophage application in food products is safe for human health (Hagens and Loessner, 
2010). However, consumer acceptability, narrow host range (Janež and Loc-Carrillo, 2013) and 
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the possibility of resistance development (El-Shibiny et al., 2009) impedes industry wide 
application.   
Vaccination  
 Vaccination could be another effort to reduce or eliminate Campylobacter. It has been 
proposed that maternal antibody against Campylobacter plays an important role in preventing 
Campylobacter colonization in the early stage of life in chicken (Sahin et al., 2003b). Several 
investigations have been conducted on the possible use of vaccination but have had limited 
success. A research article reported cecal Campylobacter reduction by approximately 2 log 
CFU/g of cecal contents after administration of killed C. jejuni whole cells and flagellin vaccine 
intraperioneally at the age of 16 and 29 day of age (Widders et al., 1996). Similarly, formalin 
inactivated C. jejuni vaccine administered orally in broiler chickens reduced intestinal 
colonization ranging from 16 to 93% compared with a non-vaccinated control group (Rice et al., 
1997). A study conducted by Wyszyńska and colleagues (2004) found that oral immunization 
(on the day of hatch and two weeks after primary immunization) with an avirulent Salmonella 
vaccine strain carrying the C. jejuni cjaA gene significantly reduced cecal Campylobacter counts. 
In addition, researchers have demonstrated an increase in anti-Campylobacter secretory IgG with 
inactivated whole cell vaccine (Widders et al., 1996; Rice et al., 1997) or both IgG and IgA after 
recombinant Salmonella vaccination (Wyszyńska et al., 2004). Recombinant vaccine candidates 
which elicit better humoral response produce better results in recent studies (Wyszyńska et al., 
2004; Layton et al., 2011). Vaccines against Campylobacter colonization in poultry are not 
commercially available yet. Further research in the development of effective vaccines against C. 
jejuni is warranted and should be feasible economically and practical for use in the poultry 
industry. 
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Natural compounds 
 Medium Chain Fatty Acids. Medium chain fatty acids (MCFAs) such as caproic, 
caprylic, capric, lauric, etc., possess antimicrobial activity against various microorganisms 
making them a viable alternative to antibiotics (Bergsson et al., 1998; Decuypere and Dierick, 
2003). One extensively studied MCFA is caprylic acid (eight-carbon saturated fatty acid), also 
known as octanoic acid which is naturally present in coconut oil, palm-kernel oils, bovine and 
breast milk (Jensen et al., 1990; Sprong et al., 2001; Jensen, 2002). Caprylic acid is classified as 
a generally regarded as safe (GRAS) compound by Food and Drug Administration (21 
CFR184.1025, FDA, 2014). Cecal Campylobacter counts were reduced by 3-4 log CFU/g by 
therapeutic or prophylactic supplementation of various concentrations of caprylic acid in feed 
(Solis de los Santos et al., 2008a, b, 2009, 2010). Similarly, a study conducted by Molatová and 
co-workers (2011) concluded that feed supplementation with an encapsulated or non-capsulated 
mixture of capric and caprylic acid (1:1) reduces cecal Campylobacter colonization consistently 
for 4 days post-inoculation of Campylobacter, with better results obtained from the encapsulated 
mixture. In contrast, Hermans and co-workers (2010) observed no significant efficacy of caprylic 
acid against cecal Campylobacter colonization despite marked in-vitro anti-Campylobacter 
activity. A study by Metcalf and co-workers (2011) reported water administration of the soluble 
form of caprylic acid produced an inconsistent reduction in cecal Campylobacter counts, in vivo. 
It has been hypothesized that the water soluble form of caprylic acid does not consistently reduce 
Campylobacter counts due to the protective action of intestinal mucus, making Campylobacter 
less susceptible to MCFAs. (Van Deun et al., 2008; Hermans et al., 2010). Mixed results 
obtained from various studies on potential use caprylic acid and its soluble form to reduce cecal 
Campylobacter suggests the need for further studies in this area.   
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 Plant extracts. In the last few decades consumer awareness and preference towards 
organic food products in addition to increased pressure to find alternative to antibiotic use in 
animals has led researchers to evaluate the antimicrobial properties of plant extracts (Atterbury et 
al., 2003b; Sirsat et al., 2009). The phytochemicals from various medicinal plants possess 
antimicrobial properties (Cowan, 1999). Use of medicinal plants by humans has a long history 
and it has been observed that other primates repeatedly consume certain plants which have 
medicinal properties (Glander, 1994; Baker, 1996; Halberstein, 2005). Friedman and colleagues 
(2002) evaluated the antimicrobial activity of various plant essential oils against several food-
borne pathogens including Salmonella typhimurium, Escherichia coli, Listeria monocytogenes 
and Campylobacter jejuni, in vitro. Similarly, a study conducted by Johny and co-workers (2010) 
on the effect of trans-cinnamaldehyde, eugenol, carvacrol and thymol against C. jejuni in cecal 
contents demonstrated significant reductions of C. jejuni, in vitro. However, these compounds 
did not produce consistent results in bird studies conducted by various researchers (Metcalf, 
2008; Hermans et al., 2011; Arsi et al., 2014). Similarly, Woo-Ming (2012) reported efficacy of 
cranberry extracts against C. jejuni, in vitro, but not in vivo. It has been suggested that the failure 
of plant extracts to work in these in vivo trials may be due the compounds being absorbed in the 
upper digestive tract and unable to reach the target site (ceca) in adequate concentrations to 
reduce C. jejuni counts (Woo-Ming, 2012). More research is needed to determine the most 
effective plant extracts and the appropriate administration strategy to reduce cecal 
Campylobacter counts in poultry production. 
Probiotics 
 ‘Probiotic’ means ‘for life’ in Greek and has been described many ways by multiple 
scientists over time (Fuller, 1992). Almost a century ago, Metchnikoff (1907) first described the 
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beneficial effect of consuming fermented milk on human health. Lilley and Stillwell (1965) first 
used the term ‘probiotic’ to describe the secretory substances produced by one microorganism 
that promotes the growth of other microorganisms. Later on, “probiotic” has been redefined as 
“microbial growth stimulating tissue extract” (Sperti, 1971) or “microorganisms and substances 
that contributes to intestinal microbial balance” (Parker, 1974). The terminology has been well 
defined over the last few decades. The extensively used definition of probiotic as given by Fuller 
is “live microorganisms which when administered in adequate amounts can confer beneficial 
effects on host health” (Fuller, 1989). Salminen and colleagues (1998) redefined probiotics as “a 
live microbial food ingredient which is beneficial to health”.  
 More than four decades ago, Nurmi and Rantala (1973) demonstrated that administration 
of probiotics (undefined mixture of bacteria from adult birds) at an early age can prevent the 
colonization of Salmonella Infantis in chickens. The precise mechanism by which probiotics 
produce beneficial effects is not clearly elucidated.  However, some researchers predict that 
probiotics provide beneficial effects by producing bacteriocins (Meghrous et al., 1990), reducing 
pH due to production of metabolites such as organic acids (Sanders, 1993), by competing for 
substrates or attachment sites (Fooks and Gibson, 2002) or by increasing macrophage mediated 
phagocytic activity (Hatcher and Lambrecht, 1993). Initially, this concept was used to control 
Salmonella infection in poultry (Nurmi and Rantala, 1973; Impey et al., 1982; Nurmi et al., 
1992; Blankenship et al., 1993; Stavric and D'aoust, 1993; Hume et al., 1998). Lately, this 
concept is being used to reduce the prevalence of various enteric pathogens such as E. coli 
(Soerjadi et al., 1981; Hakkinen and Schneitz, 1996), Clostridium perfringens (La Ragione and 
Woodward, 2003) and C. jejuni (Soerjadi-Liem et al., 1984; Stern et al., 2001a). Even though 
probiotic strains reduced Campylobacter in vitro, most of them failed to demonstrate similar 
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efficacy against Campylobacter in vivo (Santini et al., 2010; Robyn et al., 2012). One possible 
reason for such variability in in vivo studies may be due to failure of probiotics to survive the 
acidic pH of the upper gastrointestinal tract (Ding and Shah, 2009). Recent studies from our 
laboratory demonstrated that protecting the probiotic isolates from stomach acids by making 
them available in the lower intestinal tract via intercloacal transfer significantly reduced C. jejuni 
colonization in broiler chickens (Arsi et al., 2015). 
 Several investigations on probiotics against Campylobacter jejuni colonization 
emphasized the need to develop effective probiotics through better screening methods and/or by 
using effective methods of probiotic administration. It has been found that mucin (mucus 
glycoprotein) acts as a chemoattractant to C. jejuni and provides a source of carbon and energy 
for the growth of Campylobacter (Berry et al., 1988; Hugdahl et al., 1988). Research findings 
also suggest the affinity of Campylobacter spp. towards mucin as an essential factor for both 
colonization and infection (Slomiany et al., 1987; Sylvester et al., 1996). We hypothesized that 
probiotic bacteria with affinity towards mucin may competively inhibit Campylobacter at the 
preferred sites of colonization. Thus, selecting bacterial isolates with affinity to utilize and grow 
in the presence of mucin could be an effective strategy to reduce Campylobacter jejuni in 
poultry.    
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ABSTRACT 
 Campylobacter is the leading cause of foodborne illness worldwide and is often 
associated with consumption and/or mishandling of contaminated poultry products. Probiotic use 
in poultry has been an effective strategy in reducing other enteric foodborne pathogens but not 
consistently for Campylobacter. As Campylobacter resides and utilizes intestinal mucin for 
growth, isolates selected on the basis of mucin utilization might be a strategy to screen for 
efficacious probiotic bacterium. In this study, bacterial isolates demonstrating increased growth 
rates in mucin, in vitro (trials 1 or 2), or isolates demonstrating a reduction of Campylobacter 
counts when co-incubated with mucin, in vitro (trials 3 or 4) were selected for their ability to 
reduce Campylobacter colonization in four bird trials.  In trials 1 or 2, ninety day-of-hatch chicks 
were randomly divided into 9 treatment groups (n=10 chicks/treatment) and treated individually 
with one of four bacterial isolates (Bacillus sp.) demonstrating increased growth in media 
containing mucin.  The treatments included a positive Campylobacter control (no isolate) or four 
isolates grown in media with or without mucin prior to inoculation. In trials 3 or 4, sixty day-of-
hatch chicks were divided into six treatment groups (n=10 chicks/treatment) receiving either no 
isolate (positive Campylobacter control) or dosed with five individual isolates all demonstrating 
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the ability to reduce Campylobacter counts when co-incubated with mucin, in vitro.  These 
isolates were grown in media containing mucin prior to inoculation.  In all four trials, birds were 
gavaged with individual isolates at day-of-hatch and orally challenged with a four strain mixture 
C. jejuni on day 7. Ceca were collected at day 14 for Campylobacter enumeration. Results from 
these first two trials demonstrated two individual isolates, one with increased growth rates when 
grown in mucin or one isolate incubated without mucin, consistently reduced cecal 
Campylobacter counts (1.5 to 4 log reduction) when compared with controls.  In follow-up trials 
with isolates selected for their ability to directly reduce Campylobacter counts when co-
incubated with mucin, in vitro, one isolate consistently reduced cecal Campylobacter counts by 
approximately 1.5 logs. These results support the potential use of mucin to preselect isolates for 
their ability to reduce enteric Campylobacter colonization. 
 
Key words: Campylobacter; Probiotic; Chicken, mucin  
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INTRODUCTION 
 Campylobacter infections are one of the leading causes of bacterial gastroenteritis in 
humans worldwide (WHO, 2011; CDC, 2013). In the United States alone, 1.3 million cases of 
human Campylobacter infections have been reported annually (CDC, 2013). More than 17 
Campylobacter spp. has been identified (Lastovica, 2006; Debruyne et al., 2008), of which, 
Campylobacter jejuni alone is responsible for approximately 95-99% of cases of human 
campylobacteriosis (Friedman, 2000; Park, 2002; Snelling et al., 2005). Most of the 
Campylobacter enteritis cases are self-limiting (Allos and Blaser, 1995; Coker et al., 2002; 
Rosenquist et al., 2003), however, some severe post-infectious sequelae such as, Guillain-Barré 
syndrome and reactive arthritis have been reported (Rhodes and Tattersfield, 1982; Butzler, 
2004; Pope et al., 2007; Ajene et al., 2013). Various sources of Campylobacter have been 
identified, among them poultry is regarded as the principal source of infection for humans (King, 
1962; Skirrow, 1977; Rosenquist et al., 2003; CDC, 2013). It has been reported that more than 
90% of the US poultry flocks are contaminated with Campylobacter jejuni (Stern et al., 2001b), 
which potentially present a serious threat for humans (Friedman et al., 2004; Mylius et al., 2007). 
Hence, reduction or elimination of Campylobacter in poultry flocks would significantly reduce 
the human incidence of campylobacteriosis (Rosenquist et al., 2003). Several preharvest 
intervention strategies such as biosecurity, bacteriocins, bacteriophages, plant extracts, vaccine, 
medium chain fatty acids, and probiotics have been evaluated aiming to reduce Campylobacter 
prevalence in poultry flocks (Widders et al., 1996; Gibbens et al., 2001; Loc Carrillo et al., 2005; 
Stern et al., 2006; Solis de los Santos et al., 2008a,b; Metcalf et al., 2011 Arsi et al., 2015a,b). 
Unfortunately, none of them are successful in completely eliminating Campylobacter from 
poultry (Hermans et al., 2011). Application of probiotic bacteria is one strategy that may 
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potentially inhibit/reduce Campylobacter colonization in poultry. Probiotics are “live 
microorganisms which when administered in adequate amounts can confer beneficial effects on 
host health” (Fuller, 1989). Probiotics effectively reduced food-borne pathogens such as, 
Salmonella, E. coli, Listeria, Clostridium, etc., (Soerjadi et al., 1981; Impey et al., 1982; 
Hakkinen and Schneitz, 1996; Hume et al., 1998a,b ). However, administration of probiotics can 
produce inconsistent reductions in Campylobacter colonization in broiler chickens (Stern et al., 
2001a ; Robyn et al., 2013; Arsi et al., 2015a). Such inconsistent results against Campylobacter 
colonization suggested the need of better screening methods of probiotic bacteria. It has been 
observed that supplementation of porcine intestinal mucin in broth media induces the cell surface 
proteins in Lactobacillus reuteri strains and improve the mucus-binding properties in vitro 
(Jonsson et al., 2001). Since Campylobacter colonizes in intestinal mucus and uses mucin as a 
source of carbon and energy (Lee et al., 1986; Beery et al., 1988; Hugdahl et al., 1988), selection 
of probiotic isolates which utilize intestinal mucin could be an effective approach to 
competitively inhibit the enteric colonization of Campylobacter.  
 The objective of this research was to screen probiotic isolates that can eliminate/reduce 
cecal Campylobacter counts in poultry. In this study we used selected bacterial isolates that are 
generally regarded as safe (GRAS) and possess efficacy against Campylobacter, in vitro. These 
isolates were further screened for their ability to utilize mucin or inhibit Campylobacter in the 
presence of mucin. Isolates which demonstrated increased growth or anti-Campylobacter activity 
in vitro, in the presence of mucin, were selected and tested in vivo.   
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MATERIALS AND METHODS 
Probiotic isolates  
 In this study, we used selected GRAS bacterial isolates (Bacillus and Lactobacillus spp.) 
with efficacy against Campylobacter, in vitro, using a soft agar overlay technique. The selected 
bacteria were isolated and identified from the cecal contents of healthy birds during earlier 
studies from our laboratory (Arsi et al., 2015a,b).  
In vitro studies 
 Screening of mucin utilizing probiotic bacteria. Sixty-eight isolates were screened for 
increased growth in the presence of mucin. The procedure involved growing selected bacterial 
isolates separately in Tryptic Soy Broth (TSB, BBL® Becton Dickinson and Company, MD) and 
in TSB supplemented with 3% porcine gastric mucin (Sigma-aldrich, St. Louis, MO). The 
isolates were incubated aerobically at 37°C for 24 h. The cultures were then serially diluted with 
Butterfield’s Buffered Phosphate Diluent (BPD, Difco™ Becton Dickinson and company, 
Sparks, MD) and plated on Tryptic Soy Agar (TSA, Difco™ Becton Dickinson and company, 
MD) for enumeration of each bacterial isolate. The four isolates which demonstrated greatest 
increase in counts in the presence of mucin were selected and evaluated in vivo.  
 Screening for bacteria with the ability to reduce Campylobacter counts when co-
incubated with mucin.  Each bacterial isolate was co-cultured with four-strain mixture of wild 
type C. jejuni in 5 mL of TSB (no mucin) and 5 mL of TSB containing 3% porcine gastric mucin 
separately. The tubes were incubated microaerophilically at 42°C for 24 h. Each co-culture was 
then serially diluted in BPD and plated on Campy Line Agar (Line, 2001) for enumeration. The 
Campylobacter colonies were enumerated and each isolate was evaluated for its efficacy to 
reduce Campylobacter when co-cultured in the presence or absence of mucin in the growth 
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media. The five isolates which demonstrated the greatest reduction of Campylobacter counts, in 
vitro, in the presence of mucin compared to non mucin media, were selected and further 
evaluated in vivo.  
In vivo studies 
 Experimental animals and housing. For all in vivo trials, day of hatch broiler male 
chicks were procured from a local commercial hatchery. Chicks were weighed at the beginning 
and at the end of each trial. Birds were raised in floor pens with pine shavings, with ad libitum 
access to feed and water throughout the 14-day trial period. 
 Experimental design. A total of 4 bird trials were conducted at the poultry farm facility 
of University of Arkansas. Four probiotic isolates which had shown higher growth in the 
presence of mucin in the broth media were selected for in vivo studies. Two replicate trials were 
conducted (trails 1 and 2) and in each trial, a total of 90 male chicks were randomly divided into 
9 treatment groups (n=10 chicks/treatment). The treatment groups include a Campylobacter 
control (Campylobacter, no isolate) and 8 treatment groups each receiving a separate bacterial 
isolate grown in the presence or absence of mucin prior to oral administration. 
 For trials 3 and 4, we selected isolates that reduced Campylobacter in vitro, in the 
presence of mucin instead of selection for increased growth in the presence of mucin. Five 
isolates which inhibited Campylobacter in vitro, in the presence of mucin in the broth media 
were selected and tested in replicate trials 3 and 4. In each trial, 60 male chicks were randomly 
divided into 6 treatment groups (n=10 chicks/ treatment) and treatment groups include control 
(Campylobacter, no isolate) and 5 treatment groups each receiving a separate isolate grown in 
the presence of mucin prior to oral. 
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 Bacterial dosing in chicks. In each trial, at day of hatch, chicks from all the treatment 
groups except Campylobacter control were orally gavaged individually with 0.25 mL of specific 
probiotic isolate containing approximately 106-108 CFU/mL as previously described (Arsi et al., 
2015a). On day 7, all the chicks were orally gavaged with a cocktail of 4 strains of wild type 
Campylobacter containing approximately 108 CFU/mL organisms as previously described 
(Farnell et al., 2005). On day 14, bird’s ceca were aseptically collected for Campylobacter 
enumeration. Cecal contents were serially diluted 10-fold with BPD and plated on CLA for 
direct enumeration. Plates were incubated at 42°C under microaerophilic conditions for 48 h and 
Campylobacter colonies were enumerated and expressed as CFU/g. 
Statistical analysis  
To achieve homogeneity of variance, cecal Campylobacter jejuni counts were 
logarithmically transformed (Log CFU/mL) before analysis of data (Byrd et al., 2003). Data 
were analyzed by using the PROC GLM procedure of SAS (SAS, 2011). Treatment means were 
partitioned by least square means (LSMEANS) analysis and a probability of P < 0.05 was 
required for statistical significance. 
RESULTS 
 A total of 68 GRAS isolates were tested in vitro in this study and the four isolates (called 
isolate 1, 2, 3 and 4) which showed a greatest increase in counts when growth in mucin-
supplemented media compared with the unsupplemented media (data not shown) were selected 
for the in vivo studies in trials 1 and 2 (Table 1). In addition, the five isolates demonstrating the 
largest reduction in Campylobacter counts when incubated with mucin (data not shown) were 
selected for the in vivo studies in trials 3 and 4 (Table 2). 
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In trial 1, isolate 1 or 4 grown without mucin prior to inoculation reduced cecal 
Campylobacter counts (approximately 2-3 logs CFU/g ) whereas isolates 2, 3 or 4 incubated with 
mucin prior to inoculation reduced Campylobacter counts (approximately 2-3 logs CFU/g; Table 
1 ) when compared with the controls.   In trial 2, isolates 1, 2 or 3 grown without mucin  reduced 
Campylobacter counts by approximately 1.5 to 4 logs CFU/g in the ceca whereas only isolate 4 
incubated with mucin reduced Campylobacter counts (Table 1) compared to controls.  When 
compared across trials, isolate 1 grown without mucin or isolate 4 incubated with mucin 
consistently reduced Campylobacter counts in two separate trials (Table 1).  When isolates were 
selected based on their ability to reduce Campylobacter counts when co-incubated with mucin in 
vitro, isolates 5, 7 or 8 or isolates 5 or 6 reduced Campylobacter counts in chicks when 
compared with controls for trials 3 or 4, respectively (Table 2). None of these isolates adversely 
affected body weight gains at 14 days of age when compared with controls (Tables 3 and 4). 
DISCUSSION  
 Campylobacter is a flagellated, highly motile, microaerophilic bacterium able to colonize 
heavily in cecal crypt mucus (Beery et al., 1988; Hugdahl et al., 1988).  One theory of why 
probiotics are ineffective against enteric Campylobacter colonization is because Campylobacters 
are sequestered in the intestinal mucus laden cyrpts and the probiotic bacteria are not able to 
penetrate and inhibit their colonization in these locations (Aguiar et al., 2013).  In an effort to 
overcome this potential issue, four bacterial isolates demonstrating the ability to inhibit 
Campylobacter growth and which grew better in mucin, in vitro, were evaluated against 
Campylobacter colonization in chickens.  These isolates were also grown in mucin media prior 
to inoculation to determine if this would enhance efficacy, possibly due to changes in gene 
expression associated with mucin co-incubation (Naughton et al., 2014).  In the first bird trial, 
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two out of four isolates grown without mucin prior to inoculation reduced cecal Campylobacter 
counts (approximately 2-3 logs CFU/g ) whereas three out of four of these isolates incubated 
with mucin prior to inoculation reduced Campylobacter counts (approximately 2-3 logs CFU/g; 
Table 1 ).  In trial 2, many of these isolates also reduced Campylobacter counts by approximately 
1.5 to 4 logs CFU/g in the ceca.  When compared across trials, two isolates consistently reduced 
Campylobacter counts in two separate trials (Table 1).  Isolate 4 was more efficacious when 
grown in mucin prior to inoculation with an approximate 1.5 to 2.5 log reduction in 
Campylobacter counts whereas isolate 1 produced a greater reduction when not incubated with 
mucin prior to inoculation with an approximate 2-4 log reduction in Campylobacter counts.  
None of these isolates adversely affected body weight gains at 14 days of age when compared 
with controls (Tables 3 and 4). 
In an effort to select isolates with even greater efficacy, follow-up trials were conducted 
selecting isolates with the ability to directly reduce Campylobacter counts when co-incubated 
with mucin, in vitro.  The five most efficacious isolates, in vitro, were evaluated in two separate 
bird trials.  In these trials, one isolate consistently reduced cecal Campylobacter counts in two 
separate trials (Table 2) by approximately 1.5 CFU/g in the ceca.  Results from these trials 
support the preselection of probiotic isolates with the ability for increased growth rates in the 
presence of mucin or the ability of isolates to inhibit Campylobacter counts when co-incubated 
with Campylobacter, in vitro.  It is unclear if incubating these preselected isolates in the presence 
mucin prior to inoculation enhances their efficacy against Campylobacter in poultry.   
Although cecal Campylobacter counts were consistently reduced by three isolates in the 
current study, these isolates where not able to eliminate Campylobacter colonization in chickens.  
It is unknown why these isolates are effective in liquid culture but do not eliminate 
  52 
Campylobacter colonization in chickens.  Although the precise mechanism by which the 
probiotic bacteria produce beneficial effects in host is not fully established, it has been proposed 
that probiotic bacteria exert beneficial effect by producing bacteriocins (Meghrous et al., 1990), 
organic acids (Sanders, 1993), by competing for substrates or attachment sites (Fooks and 
Gibson, 2002), or by increasing macrophage mediated phagocytosis (Hatcher and Lambrecht, 
1993). Other mechanisms by which they produce beneficial effects include production of volatile 
fatty acids and antimicrobial substances (Fuller, 1991).   
Probiotics also have to survive in proventriculus or gizzard at low pH condition (2.5-3.5), 
in bile salt in the small intestine during their transit (Ding and Shah, 2009) and be able to 
colonize in the ceca (Santini et al., 2010). Probiotics bacteria should be present at more than 107 
CFU/g or mL of products to elicit beneficial effects such as stimulation of the immune system 
and enteric bacterial enzyme activities (Ouwehand and Salminen, 1998).  Ding and Shah (2009) 
suggested that most of the probiotic bacteria, even acid tolerant Lactobacillus spp. are 
susceptible to low pH (pH 2) and show poor viability during their gastrointestinal passage.  
Previous research conducted in our laboratory (Arsi et al., 2015b) demonstrates that probiotic 
isolates can maintain their efficacy when administered directly into the lower intestinal tract, 
bypassing these condition in the upper tract.  The gastrointestinal tract also contains a large, 
dynamic and complex microflora (Zhu et al., 2002), which makes the gut an extremely 
competitive environment. The interaction between the various types of bacteria in gut lumen is 
complex (Berg, 1996) and these interactions may also inhibit or reduce the efficacy of probiotic 
isolates within the GI tract.   Thus, the preselected bacterial isolates administered in the current 
study may not have been able to completely eliminate Campylobacter colonization in chickens 
possibly due to a reduction in the number of isolates reaching or penetrating the cecal crypts 
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containing Campylobacter.  Even though these isolates did not eliminate Campylobacter 
colonization, they did reduce Campylobacter counts by 1.5 to 4 logs.  Risk assessment studies 
conducted by Rosenquist and his colleagues (2003) predicted that a 2 log reduction of the 
Campylobacter on chicken carcasses can reduce the human incidence by 30 times.  Therefore 
bacterial isolates demonstrating the reduction in counts produced in the current study could 
significantly reduce the incidence of this disease in humans.  
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Table 1: The effect of selected bacterial isolates on cecal Campylobacter counts (log CFU/g of 
cecal contents) in 14-day old broiler chicks (Mean ± SEM)1. 
 
 Log CFU/g (Mean±SE) 
Treatments Trial 1 Trial 2 
Campylobacter positive control 7.95±0.23a 9.19±0.15a 
Isolate 1 5.61±0.93bcd 4.98±0.81d 
Isolate 2  7.11±0.33ab 6.94±0.54c 
Isolate 3 5.79±0.95abcd 7.78±0.40bc 
Isolate 4  4.55±1.16cd 8.56±0.14ab 
Isolate 1 incubated with mucin2 6.80±0.85abc 8.37±0.23ab 
Isolate 2 incubated with mucin2 5.62±0.95bcd 8.36±0.27ab 
Isolate 3 incubated with mucin2 4.47±1.08d 9.11±0.20ab 
Isolate 4 incubated with mucin2 5.28±0.43bcd 7.89±0.24bc 
a,b,c,d Means within columns with no common superscript differ significantly (P< 0.05). 
1Chicks were orally challenged on day 7 with 0.25 mL of approximately 1 x 108 CFU/mL of a 4 
strain mixture of wild type Campylobacter jejuni (n=10/treatment group) in each trial.  
 2These isolates were incubated with mucin prior to oral challenge in chicks 
All Campylobacter data were log10 transformed for statistical analysis. 
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Table 2: The effect of selected bacterial isolates on cecal Campylobacter counts (log CFU/g of 
cecal contents) in 14-day old broiler chicks (Mean ± SEM)1. 
 
 
 
 
 
 
a,b,c Means within columns with no common superscript differ significantly (P< 0.05). 
1Chicks were orally challenged on day 7 with 0.25 mL of approximately 1 x 108 CFU/mL of a 4 
strain mixture of wild type Campylobacter jejuni (n=10/treatment group) in each trial 
2These isolates were co-incubated with mucin in the in vitro test and incubated with mucin prior 
to oral challenge in chicks 
All Campylobacter data were log10 transformed for statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
  Log CFU/g (Mean±SE) 
Treatments Trial 3 Trial 4 
Campylobacter positive control 8.16±0.24a 7.91±0.16a 
Isolate 5 co-incubated with mucin2 6.93±0.42c 6.38±0.32c 
Isolate 6  co-incubated with mucin2 8.06±0.16a 6.79±0.22bc 
Isolate 7  co-incubated with mucin2 7.27±0.26bc 7.89±0.15a 
Isolate 8  co-incubated with mucin2 7.24±0.15bc 7.4±0.22ab 
Isolate 9 co-incubated with mucin2 7.70±0.15ab 7.31±0.26ab 
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Table 3: The effect of selected bacterial isolates on body weight gain (grams) in 14-day old 
broiler chicks (Mean ± SEM)1. 
 
  Body weight gain (g) 
Treatments Trial 1 Trial 2 
Campylobacter positive control 349.5 ± 27.96abc 199.4± 14.55d 
Isolate 1 403.0±14.44a 264.4± 23.97bcd 
Isolate 2 349.5±30.53abc 279.0± 25.07bc 
Isolate 3 333.4± 22.22abc 283.6± 24.89bc 
Isolate 4 346.3±26.27abc 313.2± 21.37ab 
Isolate 1 incubated with mucin2 326.5±38.59bc 240.8± 22.76cd 
Isolate 2 incubated with mucin2 376.8±24.75ab 253.4± 24.78bcd 
Isolate 3 incubated with mucin2 352.5±24.80abc 196.6± 31.11d 
Isolate 4 incubated with mucin2 285.5±30.23c 360.4± 17.35a 
a,b,c,d Means within columns with no common superscript differ significantly (P< 0.05). 
1A total of 90 birds were randomly divided into 9 treatment groups with 10 birds in each 
treatment per trial. Chicks were weighed at the beginning and at the end of the trial period (day 
14). The average body weight gain in grams is shown in the table. 
2These isolates were incubated with mucin prior to oral challenge in chicks 
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Table 4: The effect of selected bacterial isolates on body weight gain (grams) in 14-day old 
broiler chicks (Mean ± SEM) during Trial 3 and 4. 
 
  Body weight gain (g) 
Treatments Trial 3 Trial 4 
Campylobacter positive control 319.6±21.40b 358.4±11.50a 
Isolate 5 co-incubated with mucin2 369.9±10.52a 361.1±14.26a 
Isolate 6 co-incubated with mucin2 383.2±11.14a 332.6±16.88a 
Isolate 7 co-incubated with mucin2 369.7±13.08a 347.2±13.76a 
Isolate 8 co-incubated with mucin2 364.1±15.40a 370.2±08.02a 
Isolate 9 co-incubated with mucin2 358.1±15.90a 359.4±15.29a 
a,b Means within columns with no common superscript differ significantly (P< 0.05). 
1A total of 60 birds were randomly divided into 6 treatment groups with 10 birds in each 
treatment per trial. Chicks were weighed at the beginning and at the end of the trial period (day 
14). The average body weight gain in grams is shown in the table. 
2These isolates were co-incubated with mucin in the in vitro test and incubated with mucin prior 
to oral challenge in chicks 
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"Testing the efficacy of probiotic cultures against Campylobacter colonization in chickens." 
 
In granting its approval, the IACUC has approved only the protocol provided. Should there be 
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The IACUC appreciates your cooperation in complying with University and Federal guidelines 
involving animal subjects. 
 
 
 
 
CNC/aem 
 
 
cc: Animal Welfare Veterinarian 
 
 
 
 
 
 
 
 
 
 
';, 
  65 
CONCLUSION 
In the later few decades, Campylobacter spp. has been identified as a leading cause of 
foodborne illness in the United States, and epidemiological evidence indicates that consumption 
and/or mishandling of contaminated poultry products is often associated with Campylobacter 
infection in humans. Probiotic use in poultry has been an effective strategy in reducing other 
enteric foodborne pathogens but not consistently for Campylobacter. As Campylobacter resides 
and utilizes intestinal mucin for growth, isolates selected on the basis of mucin utilization might 
be a strategy to screen for efficacious probiotic bacterium. In this study, bacterial isolates 
demonstrating increased growth rates or anti-Campylobacter property in the presence of mucin 
in broth were tested in a total of four bird trials. In both trials 1 and 2, ninety day-of-hatch chicks 
were randomly divided into 9 treatment groups (n=10/treatment) and treated individually with 
one of four bacterial isolates (Bacillus sp.) grown in media with or without mucin prior to 
inoculation or a Campylobacter positive control (no probiotics). In trials 3 and 4, sixty day-of-
hatch chicks were  divided into 6 treatment groups (n=10/treatment) and were dosed with five 
individual isolates (Lactobacillus sp.) all grown in mucin prior to inoculation or a 
Campylobacter positive control (no probiotic). All birds were gavaged with individual isolates at 
day-of-hatch and orally challenged with a four strain mixture C. jejuni on day 7. Ceca were 
collected at day 14 for Campylobacter enumeration. Campylobacter counts were logarithmically 
transformed (log10 CFU/g) and treatment means were partitioned by LSMEANS analysis (P < 
0.05). Results from these trials demonstrated three individual isolates grown in mucin prior to 
inoculation consistently reduced cecal Campylobacter counts (1.5-4 log reduction). These results 
support the potential use of preselection and growth of isolates in mucin in evaluating bacterial 
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isolates with the ability to reduce enteric Campylobacter colonization. Further research in 
probiotics is warranted to reduce/eliminate cecal Campylobacter from chicken. 
